Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131

Zacks08-31

Cellectar Biosciences, Inc. CLRB announced two presentations. The first presentation is regarding the treatment of Bing-Neel Syndrome ("BNS") with iopofosine I 131 and the second is the review of the ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2463793203?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e","is_english":true,"pubTime":"2024-08-31 01:40","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2463793203","market":"us","top_or_hot":-1,"title":"Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131","media":"Zacks","content":"<div>\n<p>Cellectar Biosciences, Inc. CLRB announced two presentations. The first presentation is regarding the treatment of Bing-Neel Syndrome (\"BNS\") with iopofosine I 131 and the second is the review of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cellectar-biosciences-present-iwwm-featuring-174000543.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cellectar Biosciences to Present at IWWM Featuring Iopofosine I 131</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCellectar Biosciences to Present at IWWM Featuring Iopofosine I 131\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-08-31 01:40 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/cellectar-biosciences-present-iwwm-featuring-174000543.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Cellectar Biosciences, Inc. CLRB announced two presentations. The first presentation is regarding the treatment of Bing-Neel Syndrome (\"BNS\") with iopofosine I 131 and the second is the review of the ...</p>\n\n<a href=\"https://finance.yahoo.com/news/cellectar-biosciences-present-iwwm-featuring-174000543.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1989764664.SGD","symbol_name":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","start_time":0,"source_url":"https://finance.yahoo.com/news/cellectar-biosciences-present-iwwm-featuring-174000543.html","article_id":"2463793203","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/rP1EV4y5.bnG6Q.bCrRgNA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/22d93c77b91a36ccc2d6a44613af467e"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2463793203","pubTimestamp":1725039600,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Cellectar Biosciences, Inc.CLRB announced two presentations. The first presentation is regarding the treatment of Bing-Neel Syndrome  with iopofosine I 131 and the second is the review of the company’s CLOVER WaM pivotal study of iopofosine I 131.The company will present these data at the 12th International Workshop on Waldenstrom’s Macroglobulinemia  on Oct. 17, 2024, in Prague, Czech Republic.In addition, Andrei Shustov MD, Cellectar’s senior vice president of medicine, will be reviewing top-line data from the fully enrolled and completed CLOVER WaM pivotal study. CLOVER WaM is the first and the largest Waldenstrom’s Macroglobulinemia  study in a highly refractory patient population.Looking at the market potential, Cellectar Biosciences’ advancement toward the development of iopofosine I 131 for WM is well-timed.In July 2024, the company announced positive results from its CLOVER WaM pivotal study evaluating io","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1989764664.SGD":"CPR Invest - Global Disruptive Opportunities A2 Acc SGD-H","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","TMDX":"TransMedics Group Inc.","LU0267386448.USD":"FIDELITY FIRST ALL COUNTRY WORLD \"A\" (USD) INC","LU2298064838.USD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (USD) INC","BK4533":"AQR资本管理(全球第二大对冲基金)","LU1868836914.USD":"CT (LUX) I AMERICAN \"3\" (USD) ACC","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc","BK4566":"资本集团","LU1868837136.USD":"CT (LUX) I AMERICAN \"8\" (USD) ACC","LU2041044095.USD":"Blackrock Circular Economy A2 USD","BK4082":"医疗保健设备","LU0058720904.USD":"联博国际健康护理基金A","LU1868836591.USD":"CT (LUX) I AMERICAN \"1U\"(USD) ACC","LU0472753341.HKD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"A\" (HKD) ACC","BK4120":"环境与设施服务","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","BK4534":"瑞士信贷持仓","LU2125910336.SGD":"Natixis Thematics Water R/A SGD","LU1868836757.USD":"CT (LUX) I AMERICAN FUND \"2\" (USD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0097036916.USD":"贝莱德美国增长A2 USD","LU1923621640.USD":"Natixis Thematics Water R/A USD","IE00B19Z8X17.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH  \"AG\" (USD) ACC","LU0289960550.SGD":"AB FCP I - GLOBAL EQUITY BLEND PORTFOLIO 'A' (SGD) ACC","CNS":"科恩-斯蒂尔斯金融","LU1951198990.SGD":"Natixis Thematics AI & Robotics Fund H-R/A SGD-H","LU0347712357.USD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (USD) ACC","BSX":"波士顿科学","BK4135":"资产管理与托管银行","LU1951200564.SGD":"Natixis Thematics AI & Robotics Fund R/A SGD","IE00BJJMRZ35.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (SGDHDG) ACC","CLRB":"Cellectar Biosciences Inc.","BK4548":"巴美列捷福持仓","LU1923623000.USD":"Natixis Thematics AI & Robotics Fund R/A USD","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU2238339852.HKD":"NINETY ONE GSF GLOBAL ENVIRONMENT \"A\" (HKD) ACC","LU2092937221.SGD":"Blackrock Circular Economy A2 SGD-H","ISRG":"直觉外科公司","LU2413666426.HKD":"BNP PARIBAS GLOBAL ENVIRONMENT \"C\" (HKD) ACC","WM":"美国废物管理","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU2244417387.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) ACC","LU2106854487.HKD":"ALLIANZ THEMATICA \"AMG\" (HKD) INC","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1868837300.USD":"CT (LUX) I AMERICAN FUND \"9\" (USD) ACC","LU0390134368.USD":"FRANKLIN GLOBAL GROWTH \"A\" (USD) ACC","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc"},"translate_title":"Cellectar Biosciences将在IWWM上展示Iopofosine I 131","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"WM":1,"ISRG":1,"CNS":1,"CLRB":1,"TMDX":1,"BSX":0.9},"content_text":"Cellectar Biosciences, Inc. CLRB announced two presentations. The first presentation is regarding the treatment of Bing-Neel Syndrome (\"BNS\") with iopofosine I 131 and the second is the review of the company’s CLOVER WaM pivotal study of iopofosine I 131.\nThe company will present these data at the 12th International Workshop on Waldenstrom’s Macroglobulinemia (IWWM) on Oct. 17, 2024, in Prague, Czech Republic.\nAbout Cellectar Biosciences’ Iopofosine I 131\nIopofosine I 131 is a potential first-in-class, novel cancer-targeting agent utilizing a phospholipid ether radioconjugate. The agent has demonstrated the ability to cross the blood-brain barrier with clinical activity in multiple hematologic malignancies that involve or occur within the central nervous system (CNS). This includes relapsed/refractory primary CNS lymphoma, which is most often the result of diffuse large B cell lymphoma infiltrating the CNS.\nMore on Cellectar Biosciences’ Presentation\nAt IWWM, a case study report will be presented by Jorge Castillo MD, associate professor of medicine at Harvard Medical School and clinical director of Bing Center for Waldenstrom’s Macroglobulinemia Dana Farber Cancer Institute. He will be demonstrating complete CNS clearance in a relapsed/refractory BNS patient treated with iopofosine I-131. The title of his presentation is “Treatment With lopofosine I-131 in a Patient with Bing-Neel Syndrome, A Rare Manifestation of Waldenstrom Macroglobulinemia: A Case Report.”\nIn addition, Andrei Shustov MD, Cellectar’s senior vice president of medicine, will be reviewing top-line data from the fully enrolled and completed CLOVER WaM pivotal study. CLOVER WaM is the first and the largest Waldenstrom’s Macroglobulinemia (WM) study in a highly refractory patient population.\nFor investors’ note, WM is a B-cell malignancy characterized by bone marrow infiltration with clonal lymphoplasmacytic cells that produce a monoclonal immunoglobulin M (IgM) that remains incurable with available treatments. BNS is a rare, life-threatening complication of WM that grows in the CNS. The treatment of BNS requires the use of agents capable of penetrating the blood-brain barrier and typically in doses that are hard to tolerate in the elderly patient population.\nIndustry Prospects Favor Cellectar Biosciences\nPer the Mordor Intelligence report, the WM treatment market is anticipated to witness a CAGR of 5.2% during 2022-2027. Primary factors driving market growth include the increasing prevalence and incidence of cases of WM and increasing drug approvals by the regulatory bodies. Furthermore, the rising geriatric population is also expected to propel market growth.\nLooking at the market potential, Cellectar Biosciences’ advancement toward the development of iopofosine I 131 for WM is well-timed.\nImage Source: Zacks Investment Research\n \nOther Recent Developments by Cellectar Biosciences\nIn July 2024, the company announced positive results from its CLOVER WaM pivotal study evaluating iopofosine I 131. The 98% disease control rate and 80% overall response rate achieved in this pivotal study with the utilization of just four doses of iopofosine monotherapy in multi-class refractory patients seem very compelling. The result demonstrates impressive deep and durable responses, with a high proportion of patients remaining treatment-free.\nEarlier this year, Cellectar Biosciences entered into a strategic partnership with City of Hope Cancer Center in the United States. The collaboration will focus on the clinical development of Cellectar’s iopofosine I 131 in mycosis fungoides , a rare form of non-Hodgkin’s lymphoma that affects the skin and, in some patients, internal organs and blood.\nPrice Performance of CLRB\nShares of CLRB have risen 21.6% in the past year compared with the industry’s 12.5% growth.\nCLRB’s Zacks Rank & Key Picks\nCLRB currently carries a Zacks Rank #3 (Hold).\nSome better-ranked stocks in the broader medical space are Intuitive Surgical ISRG, TransMedics Group TMDX and Boston Scientific BSX. Intuitive Surgical and TransMedics sport a Zacks Rank #1 (Strong Buy) each, and Boston Scientific currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.\nIntuitive Surgical’s shares have surged 52.9% in the past year. Estimates for the company’s earnings have remained constant at $6.67 per share for 2024 in the past 30 days.\nISRG’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 8.97%. In the last reported quarter, it posted an earnings surprise of 16.34%.\nEstimates for TransMedics’ 2024 earnings per share (EPS) have moved up 48.1% to $1.20 in the past 30 days. Shares of the company have risen 155% in the past year compared with the industry’s 8.6% growth.\nTMDX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 287.50%. In the last reported quarter, it delivered an earnings surprise of 66.67%.\nEstimates for Boston Scientific’s 2024 EPS have increased 1.7% to $2.40 in the past 30 days. In the past year, shares of BSX have risen 48.6% compared with the industry’s 12.5% growth.\nIn the last reported quarter, BSX delivered an earnings surprise of 6.90%. BSX’s earnings surpassed estimates in each of the trailing four quarters, the average surprise being 7.18%.\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nBoston Scientific Corporation (BSX) : Free Stock Analysis Report\nIntuitive Surgical, Inc. (ISRG) : Free Stock Analysis Report\nCellectar Biosciences, Inc. (CLRB) : Free Stock Analysis Report\nTransMedics Group, Inc. (TMDX) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2463793203"}